Effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19: A retrospective cohort study.
World J Clin Cases
; 9(15): 3546-3558, 2021 May 26.
Article
in English
| MEDLINE | ID: covidwho-1244997
ABSTRACT
BACKGROUND:
The effectiveness of adjunctive corticosteroid use in patients with coronavirus disease 2019 (COVID-19) remains inconclusive.AIM:
To investigate the effectiveness of adjunctive corticosteroid therapy in patients with severe COVID-19.METHODS:
We conducted a retrospective analysis of the difference in several outcomes between patients with severe COVID-19 who received corticosteroid therapy (the corticosteroid group) and patients with severe COVID-19 who did not receive corticosteroid therapy (the non-corticosteroid group).RESULTS:
Seventy-five patients were included in this study. Of these, 47 patients were in the corticosteroid group and 28 patients were in the non-corticosteroid group. There were no differences between the two groups in the total length of hospital stay, the length of intensive care unit stay, high-flow oxygen days, non-invasive ventilator days, invasive ventilation days, and mortality rate. Total lesion volume ratio, consolidation volume ratio and ground-glass opacity volume ratio in the corticosteroid group decreased significantly on day 14, while those in the non-corticosteroid group did not show a significant decrease.CONCLUSION:
Our results show that adjunctive corticosteroid use did not significantly improve clinical outcomes in severe COVID-19 patients, but might promote the absorption of pulmonary lesions. Larger multicenter randomized controlled studies may be needed to confirm this.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
World J Clin Cases
Year:
2021
Document Type:
Article
Affiliation country:
Wjcc.v9.i15.3546
Similar
MEDLINE
...
LILACS
LIS